Medication info

Esmet Tablet 50/500 mg

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.7mg / 1 tabletMetformin Hydrochloride with Colloidal Anhydrous Silica›505mg / 1 tablet
Manufacturer / importer
Boryung Biopharma Co., Ltd.
Appearance
Bright pink oval film-coated tablet
Packaging
30 tablets/box[(10 tablets/PTP x 3)]
Approval status
Active

MFDS item code 202200308 · Approved 2022.01.19 · Insurance code 670502470

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, determine the dose of this medicine based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. The initial dose of this medicine should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no previous history of antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, or for whom sitagliptin monotherapy does not provide adequate glycemic control, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Patients Who Must Not Take This Medicine). 2. Patients receiving metformin: - For patients who do not achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg) together with the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin. 3. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg); the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When administered with a sulfonylurea or insulin, consider reducing the dose of the sulfonylurea or insulin to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this medicine. Any change in treatment for type 2 diabetes may alter glycemic control; use caution and ensure appropriate monitoring. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment with this medicine should not be initiated because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, discontinue this medicine immediately. Patients with hepatic impairment This medicine must not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Must Not Take This Medicine).

Ingredients

Manufacturer
Boryung Biopharma Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

  • Difficulty controlling blood sugar
  • type 2 diabetes
View approved original text

This medication is used in conjunction with dietary and exercise therapies to help control blood sugar in patients with type 2 diabetes. It is particularly useful for patients who have not previously received diabetes medication and struggle to control blood sugar with monotherapy. Additionally, it can be used when blood sugar control is inadequate with metformin or sitagliptin monotherapy, or when substituting the combination therapy of these two. This medication can also be co-administered when blood sugar control is difficult with metformin and sulfonylurea or metformin and thiazolidinedione combination therapy. When used in combination with insulin and metformin, if sufficient blood sugar control is not achieved, this medication can be added to help maintain control. In summary, this medication effectively improves blood sugar control in type 2 diabetes patients who have difficulty achieving adequate blood sugar control with various existing therapies.

How to take

Adult dose

For antidiabetic therapy, determine the dose of this medicine based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. The initial dose of this medicine should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no previous history of antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, or for whom sitagliptin monotherapy does not provide adequate glycemic control, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Patients Who Must Not Take This Medicine). 2. Patients receiving metformin: - For patients who do not achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg) together with the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin. 3. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg); the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When administered with a sulfonylurea or insulin, consider reducing the dose of the sulfonylurea or insulin to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this medicine. Any change in treatment for type 2 diabetes may alter glycemic control; use caution and ensure appropriate monitoring. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment with this medicine should not be initiated because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, discontinue this medicine immediately. Patients with hepatic impairment This medicine must not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Must Not Take This Medicine).

Precautions

This medication may cause severe allergic reactions after administration, so if symptoms such as skin rash, hives, or difficulty breathing occur, use should be stopped immediately and a physician consulted. Additionally, serious pancreatic disease, such as pancreatitis, can rarely occur, so if sudden abdominal pain, nausea, or vomiting occurs, it is important to inform healthcare personnel immediately. This medication should not be used in patients with moderate to severe kidney dysfunction or those at risk of acute renal failure, and periodic kidney function tests should be performed; if abnormalities are detected, administration must be discontinued. Patients with heart failure or unstable cardiovascular conditions, as well as those with severe infections or dehydration, should not use this medication. This medication should not be used by women who are pregnant or breastfeeding, and safety and efficacy have not been established for children and adolescents under 18 years of age. During the administration of this medication, symptoms of hypoglycemia should be carefully monitored, particularly when used with other hypoglycemic agents or insulin, as the risk of hypoglycemia may increase, necessitating frequent blood sugar checks. Additionally, gastrointestinal side effects such as diarrhea, nausea, vomiting, and abdominal pain may occur with this medication; if symptoms are severe, consultation with a physician is recommended. Alcohol consumption may increase the risk of side effects from this medication, so it is important not to overindulge during administration. Administration of this medication should be suspended for a period before and after surgery, and should only resume once the patient's condition is stabilized and kidney function is confirmed to be normal. While taking this medication, regular blood tests and kidney function tests are necessary to detect abnormalities early and take appropriate action. Drug interactions may occur when combined with certain medications; therefore, it is essential to inform healthcare personnel of any other medications being taken. Finally, it is very important for patients taking this medication and their guardians to fully understand the potential side effects and symptoms, and to consult healthcare personnel immediately if any abnormal symptoms occur.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory infection
  • headache
  • nausea
Show 21 more
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • constipation
  • severe and disabling arthralgia
  • vesicular pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • dermatitis
  • anorexia
  • weight loss
  • dyspnea
  • unstable angina
  • dizziness
  • acute renal failure
  • decreased appetite
  • itching

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent air or moisture from entering. It is important to maintain a storage temperature between 1 degree and 30 degrees Celsius. This will help preserve the medication's effectiveness for a longer period.

Appearance and packaging

Appearance

Bright pink oval film-coated tablet

Package unit

30 tablets/box[(10 tablets/PTP x 3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.